Direct block of hERG potassium channels by the protein kinase C inhibitor bisindolylmaleimide I (GF109203X)

Department of Cardiology, Medical University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany.
Cardiovascular Research (Impact Factor: 5.94). 12/2004; 64(3):467-76. DOI: 10.1016/j.cardiores.2004.07.023
Source: PubMed


The human ether-a-go-go-related gene (hERG) encodes the rapid component of the cardiac repolarizing delayed rectifier potassium current, I(Kr). The direct interaction of the commonly used protein kinase C (PKC) inhibitor bisindolylmaleimide I (BIM I) with hERG, KvLQT1/minK, and I(Kr) currents was investigated in this study.
hERG and KvLQT1/minK channels were heterologously expressed in Xenopus laevis oocytes, and currents were measured using the two-microelectrode voltage clamp technique. In addition, hERG currents in stably transfected human embryonic kidney (HEK 293) cells, native I(Kr) currents and action potentials in isolated guinea pig ventricular cardiomyocytes were recorded using whole-cell patch clamp electrophysiology.
Bisindolylmaleimide I blocked hERG currents in HEK 293 cells and Xenopus oocytes in a concentration-dependent manner with IC(50) values of 1.0 and 13.2 muM, respectively. hERG channels were primarily blocked in the open state in a frequency-independent manner. Analysis of the voltage-dependence of block revealed a reduction of inhibition at positive membrane potentials. BIM I caused a shift of -20.3 mV in the voltage-dependence of inactivation. The point mutations tyrosine 652 alanine (Y652A) and phenylalanine 656 alanine (F656A) attenuated hERG current blockade, indicating that BIM I binds to a common drug receptor within the pore region. KvLQT1/minK currents were not significantly altered by BIM I. Finally, 1 muM BIM I reduced native I(Kr) currents by 69.2% and lead to action potential prolongation.
In summary, PKC-independent effects have to be carefully considered when using BIM I as PKC inhibitor in experimental models involving hERG channels and I(Kr) currents.

Download full-text


Available from: Christoph Karle, Sep 18, 2014
19 Reads
    • "Whole-cell patch clamp recordings from HEK 293 cells were carried out using a RK-400 amplifier (Bio-Logic SAS, Claix, France) as reported (Thomas et al., 2004a; Gierten et al., 2008; Schmidt et al., 2012; Seyler et al., 2012). "
    Biophysical Journal 01/2015; 108(2):110a. DOI:10.1016/j.bpj.2014.11.623 · 3.97 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mutations in ryanodine receptor calcium ion-release channels (RyR2) have emerged as important causative players in exercise/stress-induced ventricular arrhythmia leading to sudden cardiac death (SCD). Thus, RyR2 represents an attractive therapeutic target, and a detailed understanding of the mechanistic basis of RyR2 dysfunction at the molecular, cellular and organ level is essential for the development of novel, more effective therapeutic approaches to prevent arrhythmia and SCD. Such advances will translate into a tremendous improvement in the survival and quality of life of SCD-susceptible individuals. In this review, the authors consider how recent knowledge gained from mutation identification, phenotypic manifestation and functional evaluation of RyR2 mutants, are being used to develop novel therapeutic strategies in RyR2-dependent arrhythmia.
    Future Cardiology 07/2005; 1(4):531-41. DOI:10.2217/14796678.1.4.531
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: The objective of this study was to identify the extent to which propofol alters intracellular free Ca2+ concentration ([Ca2+]), myofilament Ca2+ sensitivity, and contraction of individual cardiomyocytes during activation of alpha(1a) adrenoreceptors and to determine the cellular mechanism of action. Methods: Freshly isolated ventricular myocytes were obtained from adult rat hearts. Myocyte shortening and [Ca2+](i) were simultaneously monitored in individual cardiomyocytes; exposed to phenylephrine after treatment with chloroethylclonidine (alpha(1b)-adrenoreceptor antagonist) and BMY 7378 (aid-adrenoreceptor antagonist). Data are reported as mean +/- SD. Results: Phenylephrine increased myocyte shortening by 124 +/- 9% (P = 0.002), whereas peak [Ca2+]i only increased by 8 +/- 3% (P = 0.110). Inhibition of phospholipase A(2) and phospholipase C attenuated the phenylephrine-induced increase in shortening by 84 +/- 11% (P = 0.004) and 15 +/- 6% (P = 0.010), respectively. Inhibition of protein kinase C (PKC) and Rho kinase attenuated the phenylephrine-induced increase in short-ening by 17 +/- 8% (P = 0.010) and 74 +/- 13% (P = 0.006), respectively. in the presence of phenylephrine, propofol increased shortening by 40 +/- 6% (P = 0.002), with no concomitant increase in [Ca2+](i). PKC inhibition prevented the propofol-induced increase in shortening. Selective inhibition of PKC alpha, PKC delta, PKC epsilon, and PKC reduced the propofol-induced increase in shortening by 12 +/- 5% (P = 0.011), 36 +/- 8% (P = 0.001), 32 +/- 9% (P = 0.007), and 19 5% (P = 0.008), respectively. Na+-H+ exchange inhibition reduced the propofol-induced increase in shortening by 56 +/- 7% (P = 0.001). Conclusion: Activation of alpha(1a) adrenoreceptors increases cardiomyocyte shortening primarily via a phospholipase A(2)-dependent, Rho kinase-dependent increase in myofilament Ca2+ sensitivity. Propofol further increases myoftlament Ca2+ sensitivity and shortening via a PKC-dependent pathway and an increase in Na+-H+ exchange activity.
    Anesthesiology 08/2005; 103(2):335-343. DOI:10.1097/00000542-200508000-00017 · 5.88 Impact Factor
Show more